Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says

Executive Summary

The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments

You may also be interested in...



AHRQ NSAID final report

Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...

AHRQ NSAID final report

Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...

Osteoporosis Drugs Found To Be Equally Effective – AHRQ Report

An Agency for Healthcare Research & Quality draft report on osteoporosis treatments found that bisphosphonates are not demonstrably superior to less costly treatments

Related Content

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel